NEW YORK, June 16, 2026
AccurKardia announced that its AK-AVS™ aortic valve stenosis screening software has been accepted into the U.S. Food and Drug Administration’s Total Product Life Cycle Advisory Program (TAP), a program designed to accelerate the development and commercialization of breakthrough medical technologies. The AI-powered software previously received FDA Breakthrough Device Designation and is designed to identify moderate to severe aortic valve stenosis (AVS) using data obtained from routine 12-lead electrocardiograms (ECGs). Acceptance into the TAP program provides AccurKardia with enhanced regulatory engagement, earlier FDA collaboration, and opportunities to streamline development and reimbursement pathways, potentially bringing the technology to patients more quickly.
AI-Powered ECG Screening Targets Underdiagnosed Heart Valve Disease
Aortic valve stenosis is one of the most common and serious valvular heart diseases, particularly among older adults. The condition often progresses silently, with many patients remaining asymptomatic until the disease reaches advanced stages. Current diagnosis relies heavily on echocardiography, which is not routinely performed for large populations. AK-AVS aims to address this challenge by leveraging the widespread availability of ECG data already stored within healthcare systems. By analyzing routine ECG recordings through advanced artificial intelligence algorithms, the software can help clinicians identify patients who may require follow-up echocardiography, enabling earlier diagnosis and intervention before severe complications occur.
Clinical Data Demonstrates Potential for Earlier Detection
Recent research conducted at Baylor St. Luke’s Medical Center demonstrated the potential clinical value of AK-AVS. Investigators found that the software was able to flag patients with aortic valve stenosis up to 4.5 years before treatment, highlighting its ability to identify disease earlier than traditional care pathways. Earlier recognition of moderate to severe AVS can significantly improve patient management and outcomes by enabling timely specialist referrals, closer monitoring, and appropriate therapeutic interventions. Cardiologists believe that ECG-based screening tools could help optimize healthcare resources by directing echocardiography toward patients most likely to benefit from additional evaluation.
Advertisement
Expanding the ECG as a Diagnostic Biomarker Platform
The acceptance of AK-AVS into the FDA TAP program marks AccurKardia’s second breakthrough-designated device to enter the initiative, following the inclusion of its AK+ Guard™ hyperkalemia detection software in 2025. The milestone strengthens the company’s strategy of transforming the traditional ECG into a broader diagnostic biomarker platform capable of identifying multiple serious health conditions beyond conventional cardiac rhythm analysis. AccurKardia’s growing portfolio includes AccurECG™ 2.0, an FDA-cleared software-as-a-medical-device solution for automated ECG interpretation, alongside investigational AI-driven tools targeting cardiovascular and metabolic disorders. With continued FDA engagement and expanding clinical evidence, the company aims to advance ECG-based diagnostics as a scalable approach for earlier disease detection and improved patient outcomes across healthcare systems worldwide.
Source: AccurKardia press release
